ANDA 75690, held by Actavis Mid Atlantic. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 75690 (Fluoxetine Hydrochloride), held by Actavis Mid Atlantic, was first approved by FDA on Jan 31, 2002, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 31, 2002 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluoxetine HydrochlorideEQ 20MG BASE/5ML · solution;oral | Fluoxetine Hydrochloride | Discontinued |
| Aug 18, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 20, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 17, 2002 | Supplement 1Manufacturing | Approved | None posted |
| Jan 31, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters